Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Binary Oncolytic Adenovirus in Combination With HER2-Specific CAR VST, Advanced HER2 Positive Solid Tumors (VISTA) (VISTA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03740256
Recruitment Status : Not yet recruiting
First Posted : November 14, 2018
Last Update Posted : November 29, 2018
Sponsor:
Collaborators:
The Methodist Hospital System
Texas Children's Hospital
Information provided by (Responsible Party):
Andrew Sikora, Baylor College of Medicine

Brief Summary:

This study involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. Because there is no standard treatment for this cancer at this time or because the currently used treatments do not work fully, this study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor-modified Adenovirus-specific cytotoxic T lymphocytes (HER2-AdVST), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2-AdVST react to the tumor.

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: oncolytic adenovirus (CAdVEC) and T cells (HER2-AdVST).

CAdVEC is an oncolytic adenovirus that has been modified to include additional immune system stimulators. Specifically, genes that stimulate the immune system have been added to the oncolytic adenovirus. Oncolytic adenoviruses are viruses that are made to target and kill cancer cells without killing normal cells. Other oncolytic adenoviruses have been used in patients before however CAdVEC has not. In this study, CAdVEC will be injected into participants tumor at one tumor site which is most easiest to reach. Once the oncolytic adenovirus infects the cancer cells, the genes will be expressed, resulting in activation of the immune response so it can attack and kill cancer cells. However, because this approach may have limited effects on the other tumor sites that have not received the oncolytic virus injection, patients will also receive specific T cells following the intratumor CAdVEC injection. These T cells are special infection-fighting blood cells that can kill cells infected with viruses and tumor cells. Investigators have found from previous research that investigators can put a new gene into T cells and make them specifically recognize and kill cancer cells expressing HER2. In the past patients have signed a consent form that allowed us to put on their T cells the HER2 chimeric receptor with viral antigen receptor on their T cells. Investigators want to see if these cells can survive in a patients blood and affect the tumor. Although HER2 chimeric antigen receptor modified cytotoxic T lymphocytes have been used in patients before, HER2-AdVST has not.


Condition or disease Intervention/treatment Phase
Bladder Cancer Head and Neck Squamous Cell Carcinoma Cancer of the Salivary Gland Lung Cancer Breast Cancer Gastric Cancer Esophageal Cancer Colorectal Cancer Pancreatic Adenocarcinoma Biological: CAdVEC Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: VISTA (VIrus Specific T Cells and Adenovirus): A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific CAR VST Cells in Patients With Advanced HER2 Positive Solid Tumors
Estimated Study Start Date : January 1, 2019
Estimated Primary Completion Date : January 1, 2023
Estimated Study Completion Date : January 1, 2037

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Phase

Six dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level (see section 11.1) until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.AdVST 3 days later (Day 4), according to the following dose levels.

Dose Level 1 CAdVEC = 1.00E+10 HER2.CAR-AdVST = 0

Dose Level 2 CAdVEC = 1.00E+10 HER2.CAR-AdVST = 1.00E+06

Dose Level 3 CAdVEC = 1.00E+11 HER2.CAR-AdVST = 1.00E+06

Dose Level 4 CAdVEC = 1.00E+11 HER2.CAR-AdVST = 1.00E+07

Dose Level 5 CAdVEC = 1.00E+12 HER2.CAR-AdVST = 1.00E+07

Dose Level 6 CAdVEC = 1.00E+12 HER2.CAR-AdVST = 1.00E+08

Biological: CAdVEC
The administration of CAdVEC may create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred CAR AdVSTs via both CAR recognition of tumor antigen and TCR recognition of viral antigen. The CAR AdVSTs expanded at primary tumor sites may re-circulate and target metastasized tumors. The combination this study proposes to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cell/VST and testing each element separately would not be beneficial or informative.
Other Name: HER2.CAR AdVST




Primary Outcome Measures :
  1. Number of patients with dose limiting toxicity (DLT) by CTCAE 5.0 [ Time Frame: 6 weeks after the HER2.CAR AdVST infusion or 6 weeks + 3 days after the CAdVEC injection. ]
    Incidence of dose limiting toxicities (DLT) of CAdVEC intratumoral injection in combination with HER2.CAR AdVST cells in patients with advanced refractory HER2 positive solid tumors.


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) according to RECIST1.1 criteria [ Time Frame: 13 weeks ]
    Overall response rate is defined as the number of patients experiencing PR or better (i.e. PR + CR) divided by the number evaluable for efficacy. Tumor regression or progression will be evaluated accordingly with RECIST 1.1 criteria.

  2. Disease Control Rate (DCR) [ Time Frame: 13 weeks ]
    Disease Control Rate is defined as as the number of patients experiencing SD or better (i.e. SD+PR+CR) divided by the number evaluable for efficacy. Tumor regression or progression will be evaluated accordingly with RECIST 1.1 criteria.

  3. Progression Free Survival (PFS) [ Time Frame: 15 years ]
    Progression-Free Survival is defined as the time from start of treatment to disease progression or death.

  4. Overall Survival (OS) [ Time Frame: 15 years ]
    Overall survival is defined as the time from the start of treatment to death due to any cause.

  5. Number of treatment related adverse events with grade 3 or greater severity by CTCAE 5.0 [ Time Frame: 30 days ]
    Treatment related adverse events with grade 3 or greater severity by CTCAE 5.0



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed HER2 positive solid tumors, including but not limited to: head and neck squamous cell carcinoma; cancer of the salivary glands; lung cancer; breast cancer; bladder cancer; gastric cancer; esophageal cancer; colorectal cancer; and pancreatic adenocarcinoma. HER2 positivity is defined as ≥2+ staining by IHC with the FDA-approved 4B5 antibody (Ventana), which refers to greater than weak-to-moderate staining intensity in >10% tumor cells.
  2. The disease must be deemed by the appropriate multidisciplinary tumor board unsuitable for curative surgery, radiotherapy, systemic therapy or any combination of the above modalities.
  3. Disease must have progressed after standard first line therapy, or without available effective treatment options.
  4. The patient must have at least one tumor site appropriate for intratumoral injection.
  5. The patient must have radiographically measurable disease as per RECIST 1.1.

i.The patient must have adequate organ function within 7 days prior to consent for treatment as indicated by following measures:

  • Hematologic: Absolute neutrophil count (ANC) ≥1.0 x 10^9/l; Hemoglobin ≥9 g/dl; Platelet count ≥ 100 x 10^9/l; PT or PTT ≤ 1.5 x ULN unless the subject is receiving anticoagulation.
  • Hepatic function: bilirubin < 2 ULN, and AST and ALT < 3 ULN
  • Renal Function: serum creatinine <2 x the ULN or creatinine clearance >30 mL/min.

    f.Prior HER2 targeted therapy is allowed if delivered at least 4 weeks prior to the enrollment.

    g.Prior immunotherapy is allowed if it was delivered at least 4 weeks prior to the enrollment.

    h.Eastern Cooperative Oncology Group (ECOG) performance status 2 or less. i.Females of childbearing potential must have a negative pregnancy test and agree to use contraception during on-study protocol therapy.

    j.Male subjects with pregnant partner/female partner of childbearing potential agree to use barrier contraceptive during the study to minimize the risk of embryo-fetal exposure.

    k.The patient is ≥ 18 years of age, and able to understand and give informed consent to study related procedures and treatments.

Exclusion Criteria:

  1. Histologically confirmed HER2 positive solid tumors, including but not limited to: head and neck squamous cell carcinoma; cancer of the salivary glands; lung cancer; breast cancer; bladder cancer; gastric cancer; esophageal cancer; colorectal cancer; and pancreatic adenocarcinoma. HER2 positivity is defined as ≥2+ staining by IHC with the FDA-approved 4B5 antibody (Ventana), which refers to greater than weak-to-moderate staining intensity in >10% tumor cells.
  2. The disease must be deemed by the appropriate multidisciplinary tumor board unsuitable for curative surgery, radiotherapy, systemic therapy or any combination of the above modalities.
  3. Disease must have progressed after standard first line therapy, or without available effective treatment options.
  4. The patient must have at least one tumor site appropriate for intratumoral injection.
  5. The patient must have radiographically measurable disease as per RECIST 1.1.

i.The patient must have adequate organ function within 7 days prior to consent for treatment as indicated by following measures:

  • Hematologic: Absolute neutrophil count (ANC) ≥1.0 x 10^9/l; Hemoglobin ≥9 g/dl; Platelet count ≥ 100 x 10^9/l; PT or PTT ≤ 1.5 x ULN unless the subject is receiving anticoagulation.
  • Hepatic function: bilirubin < 2 ULN, and AST and ALT < 3 ULN
  • Renal Function: serum creatinine <2 x the ULN or creatinine clearance >30 mL/min.

    f.Prior HER2 targeted therapy is allowed if delivered at least 4 weeks prior to the enrollment.

    g.Prior immunotherapy is allowed if it was delivered at least 4 weeks prior to the enrollment.

    h.Eastern Cooperative Oncology Group (ECOG) performance status 2 or less. i.Females of childbearing potential must have a negative pregnancy test and agree to use contraception during on-study protocol therapy.

    j.Male subjects with pregnant partner/female partner of childbearing potential agree to use barrier contraceptive during the study to minimize the risk of embryo-fetal exposure.

    k.The patient is ≥ 18 years of age, and able to understand and give informed consent to study related procedures and treatments.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740256


Contacts
Layout table for location contacts
Contact: Andrew Sikora, MD 713-798-3909 Andrew.Sikora@bcm.edu

Sponsors and Collaborators
Baylor College of Medicine
The Methodist Hospital System
Texas Children's Hospital
Investigators
Layout table for investigator information
Principal Investigator: Andrew Sikora, MD Texas Children's Hospital

Layout table for additonal information
Responsible Party: Andrew Sikora, Assistant Professor, Center for Cell and Gene Therapy, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT03740256     History of Changes
Other Study ID Numbers: H-43405 VISTA
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: November 29, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Andrew Sikora, Baylor College of Medicine:
HER2
Human Epidermal Growth Factor Receptor 2
Bladder
Squamous Cell Carcinoma
Salivary Gland
Lung
Breast
Gastric
Esophageal
Colorectal
Pancreatic

Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Carcinoma, Squamous Cell
Adenocarcinoma
Urinary Bladder Neoplasms
Esophageal Neoplasms
Squamous Cell Carcinoma of Head and Neck
Adenoviridae Infections
Salivary Gland Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Urologic Neoplasms
Urogenital Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Head and Neck Neoplasms
Esophageal Diseases
DNA Virus Infections
Virus Diseases